Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3856_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
12 Мб
Скачать
☆
212
O. Doron et al.
Flowgate2 BGC). The ASTER trial documented a trend toward better mTICI 3 and better clinical outcomes in BGC-treated patients, using direct aspiration.
Aside from aspiration, stent retrievers, and a combination of the two, additional methods include distal-protection devices and rescue stenting. The “Lazarus effect cover-assisted MT” is a distal embolization protection device for stent retriever thrombectomy. It features a funnel-shaped nitinol mesh designed to surround the stent retriever and the enmeshed thrombus during retrieval.
Following stent retriever deployment, the Lazarus device is positioned at its proximal end, and the retraction of the stent retriever against the device results in it inverting and rolling over the outside of the stent retriever. This protective sheath presum­ably prevents clot fragmentation and distal embolization and has also been used with distal aspiration techniques.
Another method is “rescue stenting.” While it is uncommonly used due to reperfusion rates in AIS LVO being in the 90% range, it is practical for a subset of patients in whom recanalization fails. One of the key reasons for failure of EVT is underlying intracra­nial atherosclerotic stenosis (ICAS). ICAS is routinely diagnosed during the EVT procedure by repeated recanalization and then acute reocclusion of the vessel. In a Korean series of failed EVTs, this occurred in up to 77% of the patients. Presently, no guidelines exist for the optimum treatment in patients who failed thrombectomy. An alternate technique is to perform permanent stenting in an attempt to preserve the patency of the vessel.
The effectiveness of “rescue stenting” was demonstrated in an initial study of 45 failed thrombectomy patients, where the 17 patients with rescue stenting had better outcomes and less cere­bral herniation than the 28 non-stenting patient [61]. This tech­nique was validated in a large retrospective analysis of patients from 16 Korean stroke centers. In this study, patients with anterior circulation LVOs who failed to recanalize following EVT were split into rescue stenting and non-rescue stenting groups. Out of the 148 failed EVT patients, 48 received rescue stenting and 100 did not. Subsequent results show that 31 out of 48 rescue stenting patients (64.6%) had successful mTICI 2b-3 reperfusion with res­cue stenting, while none of the 100 patients without rescue stent-
10 Endovascular Management and Treatment of Acute Ischemic…
213
ing achieved reperfusion. Good functional outcome at 3months was observed in 39.6% of the rescue stenting group and in 22.0% of the non-rescue stenting group (p=0.031) without an increase in SICH or mortality. Moreover, in the rescue stenting group with successful reperfusion, 54.8% achieved good outcome despite the initial EVT failure, equivalent to the functional outcomes with mTICI 2b-3 reperfusion in the initial EVT attempts of 55.4%.
A meta-analysis on rescue stenting, which included articles from 2015 to 2019, supported these results. In a sample of 352 patients, there was improved outcomes in the stenting arm com­pared with the refractory occlusion arm (OR, 2.87; 95% CI,
1.77–4.66; p< 0.001; I2, 0%) with reduced mortality, but there was some heterogeneity between studies for mortality (OR, 0.39; 95% CI, 0.16–0.93; p=0.03; I2, 43%).
In a recent multinational study on emergency rescue stenting in AIS involving seven neurovascular centers, good outcome was observed in 73 out of 163 (44.8%) patients with recorded out­comes at 90 days. This is considerably better than the rates of 7–22% found in cohorts with reocclusion or persistent occlusion reports without rescue stenting. However, the rate of SICH in this analysis (11%) was higher than in the aggregated thrombectomy studies without intracranial stenting of 4.4%, and this was more common in anterior circulation occlusions than posterior circula­tion occlusions. A lower number of thrombectomy attempts before rescue stenting were correlated with better functional out­comes.
The decision to perform rescue stenting is complex, as the per­manent placement of a stent requires either acute glycoprotein 2b/3a inhibitors or dual antiplatelet treatment to prevent acute reocclusion due to in-stent thrombosis. In acute stroke patients with already sizable amounts of ischemic or infarcted tissue, these medications contribute to a potentially higher risk of symptomatic intracranial hemorrhage. Presently, there is limited data and a lack of consensus regarding antiplatelet management for intracranial stenting during thrombectomy.
As can be concluded from the heterogeneous nature of LVO AIS, there are still concerns unanswered by the guidelines. These imminent questions describe subsets of patients who are still fre-
214
O. Doron et al.
quently encountered and for whom future studies would elucidate the best treatment algorithm.

Large Ischemic Core

While the present guidelines clearly indicate that EVT should be performed for patients without a large early infarct or with an ASPECTS of six or more, there exists a substantial proportion of patients who present to the hospital with an AIS with a sizable ischemic core. While the evidence is unclear, these patients may still derive some benet from EVT.Pending the outcomes of ran­domized controlled trials, core-lab adjudicated pooled analyses of existing studies may shed preliminary insight into this crucial question.
In a study pooling data from seven randomized trials with a total of 1764 patients, of which 871 were in the EVT arm and 893in the best medical treatment arm, it was indicated that EVT was associated with better functional outcomes across a wide range of pretreatment imaging types on ordinal shift analyses [64]. This included all ASPECTS groups, except for ASPECTS 0–2, in which the low sample size was not statistically signicant. However, this should be interpreted with caution, as in patients with a large ischemic burden or ASPECTS 4 or less, EVT was associated with signicantly more SICH.
Similarly, a secondary analysis of the Optimizing Patient Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT) trial demonstrated that EVT was associated with bet­ter functional independence (mRS 0–2) compared with medical management alone (OR, 3.27; 95% CI, 1.11–9.62; p = 0.03). Moreover, EVT was also associated with less infarct growth and smaller nal infarct volume than medical treatment [66]. These aforementioned analyses provide a strong evidence to support fur­ther investigation of the use of EVT for patients with large infarcts and poor ASPECTS at baseline.
The preliminary results from these studies led to the ongoing SELECT-2 trial, which was designed to evaluate thrombectomy compared with medical management in distal ICA and MCA M1
10 Endovascular Management and Treatment of Acute Ischemic…
215
occlusions with a large core on either CT (ASPECTS 3–5) or advanced perfusion imaging (rCBF <30% or ADC<620 or 50ml or more). The tentative completion date of this trial is at the end of 2021 [67]. Other ongoing clinical trials, such as TENSION (NCT03094715), TESLA (NCT03805308), and IN EXTREMIS [68, 69], are also actively recruiting patients and will provide con­clusive evidence on the use of EVT in patients with a large isch­emic core at presentation [67].
Clinically Mild Strokes withLVO
Another subset of patients are those who present with LVOs but mild strokes clinically. These scenarios are typically dened at NIHSS threshold of <5, where the risk of the EVT procedure needs to be weighed carefully against the potential benet. A pooled data analysis was conducted featuring six comprehensive stroke centers with 300 patients having LVO and NIHSS 0–5, with 80 patients undergoing EVT and 220 patients undergoing best medical therapy [70]. The best medical treatment group allowed for rescue EVT if there was subsequent neurological deterioration. While the groups were not similar, EVT was associ­ated with better functional outcomes (OR, 3.1; 95% CI, 1.4–6.9), and in a propensity-matched analysis, the superiority of EVT over best medical treatment persisted (84.4% vs. 70.1%; P = 0.03) [64].
Recently, another meta-analysis pooled patient data from 16 centers from 2013 to 2017. This study evaluated 251 patients with LVO and mild stroke, of which 138 were treated with EVT and 113 with best medical treatment. The results demonstrated that the 3-month functional outcomes were better in the best medical treatment group when compared with the EVT group (77.4% vs.
88.5%; p= 0.02) [37]. The rate of asymptomatic ICH was also lower in the best medical management group as compared with the EVT group (4.6% vs. 17.5%; p=0.002). Moreover, there was no difference in the rate of reperfusion or in safety outcomes between the two groups [64, 66, 71].
216
O. Doron et al.
It is expected that future RCTs will further elucidate if mild strokes with LVO should be treated via EVT.One of these RCTs is ENDOLOW, which is studying anterior circulation occlusions with NIHSS scores 0–5 and is enrolling patients in Canada, the USA, Germany, and Sweden. The INEXTREMIS trial also fea­tures a sub-study that is evaluating ischemic stroke patients with an NIHSS<6 and LVO occlusions and aims to answer this impor­tant question [71].
Very Late Presenting Patients: Acute Stroke Beyond 24Hours
Recent evidence from the AURORA study, which pooled data from six randomized trials to examine effect of EVT in anterior circulation proximal LVO stroke from 6 to 24h from time last seen well, suggests a potential benet of EVT in achieving reduced disability on functional outcome in terms of mRS in this group of patients, with an adjusted common odds ratio of 2.54 (95% CI, 1.82–3.54; p<0.0001). Moreover, the number needed to treat to reduce mRS by 1 point was three patients. Furthermore, no signicant differences in mortality or SICH were seen between EVT and control groups [72]. This further validates the results of previous trials, which supported the fact that carefully selected patients benet from thrombectomy up to 24hours [61, 73].
However, there is another subset of patients who present after 24hours. Presently, no clinical trials or guidelines detailing how we can manage these patients exist. Kim etal. studied the benet of EVT in patients presenting very late [74]. In a subgroup analy­sis of 150 patients, who presented more than 16h from their last known well time, EVT was performed only in 24 patients, but a propensity-matched analysis showed it was associated with increased odds of having favorable functional recovery at 3months (adjusted OR, 11.08; 95% CI, 1.88–108.60). In a further subgroup of patients 24 hours from last known well, EVT was associated with favorable outcomes as well (adjusted OR, 10.54; 95% CI, 2.18–59.34) [75]. These preliminary studies provide evi-
10 Endovascular Management and Treatment of Acute Ischemic…
217
dence in support of a possibility of maintaining the penumbra beyond 24hours in patients with good collaterals [74].
Direct toThrombectomy Table: No IV tPA
Timing directly impacts the functional outcome in acute stroke thrombectomy, as any delay in treatment initiation negatively impacts patients’ functional outcomes [67, 76]. While IV-tPA can recanalize acute stroke occlusions, EVT has shown higher rate of recanalization. Hence, there is now a school of thought that instead of administering IV tPA, whether at an intervening pri­mary stroke center or the comprehensive stroke center, patients with AIS from an LVO should be treated with EVT.
The SKIP trial, a RCT carried out in Japan, enrolled 200 AIS patients with anterior circulation occlusions presenting within 4hours of onset [68]. At 3months, the rate of good functional outcome was similar between the direct thrombectomy (59%) and combined bridging approach (57%). Moreover, both groups were found to have a similar mortality rate. However, this trial was unable to prove noninferiority of direct to thrombectomy over bridging IV tPA (0.6mg/kg Japanese standardized dose), attribut­able to it being underpowered with a modest sample size. While the rate of asymptomatic hemorrhage and SICH did not signicantly differ between both arms, the combined rate of any ICH was signicantly lower for the EVT group.
Two other trials, similar in design to the SKIP trial were con­ducted in China, across multiple stroke centers, also studied bridging IV tPA in thrombectomy. The DIRECT-MT trial, with 656 enrolled patients, revealed that endovascular thrombectomy alone was noninferior to combined intravenous alteplase and endovascular thrombectomy when considering the functional out­come at 90days (adjusted common odds ratio, 1.07; 95% con­dence interval, 0.81–1.40; p=0.04 for noninferiority). In addition, the noninferiority margin was set at a high value of 20% margin of condence in this trial. The noninferiority test in the DEVT trial also highlighted that the endovascular thrombectomy alone was noninferior to the combined IV thrombolysis and endovascu-
218
O. Doron et al.
lar thrombectomy group (z=2.7157, p for noninferiority=0.003) [69, 70]. This trial was terminated after the rst interim analysis in May 2020 due to the outcome measured having surpassed the prespecied efcacy boundary. In this study, there was no signi­cantly different rate of symptomatic ICH between groups; how­ever, the rate of any ICH is signicantly higher in the bridging r-TPA and thrombectomy group. It is worth noting that given these trials were performed in East Asian populations, further evi­dence is needed in a more diverse population. The SWIFT­DIRECT, MR CLEAN NOIV, and DIRECT-SAFE trials are upcoming international RCTs that can fulll this role as they aim to provide more information on the adoption of thrombectomy alone approach against bridging IV tPA [70].

Tandem Occlusions

A tandem occlusion (TO) is a thromboembolic obstruction in the intracranial cerebral vasculature in combination with an extracra­nial carotid artery occlusion. It can occur in up to one-sixth of ischemic stroke patients [37]. Typically, TOs do not have good recanalization rates with IV tPA, and therefore EVT is suggested [22]. In fact, subgroup analyses of the ESCAPE and MR CLEAN studies indicated that patients with TO have better outcomes with early or concurrent treatment of the extracranial occlusion rather than later in a staged procedure [77, 78]. Nonetheless, there is a lack of consensus on the optimal endovascular procedure for acute TO.
The present issue pertains to the best method of treating TO in acute stroke. The point of contention is if it is better to initially bypass the extracranial occlusion and remove the intracranial occlusion rst before returning to tackle the extracranial stenosis (the “retrograde” approach) or if it is preferable to attempt pri­mary recanalization of the extracranial occlusion rst before mov­ing on to treat the intracranial occlusion (the “antegrade” approach). The antegrade approach uses primary stenting to jail the extracranial stenotic atheromatous plaque, thereby preventing
10 Endovascular Management and Treatment of Acute Ischemic…
219
distal emboli [78]. One potential drawback of the antegrade approach is the procedural time used for carotid stent placement, as it creates a delay in the time to intracranial reperfusion, possi­bly resulting in an increase of the nal infarct volume [75, 79]. Furthermore, stent retriever-based thrombectomy techniques have the potential of entanglement between the struts of the stent retriever and carotid stent during withdrawal if the guiding cath­eter cannot be advanced through the carotid stent. Moreover, the retrograde approach achieves intracranial recanalization faster, and some purport that this gives better functional outcomes [75]; however, it may be difcult to pass through the proximal occlu­sion, and subsequent emboli from the proximal occlusion can sometimes reocclude the intracranial circulation.
Type ofAnesthesia forThrombectomy
For patients treated with EVT particularly, anesthesia has indi­cated benets, especially when considering complex anatomy, difcult cases, or restless and aphasic patients. The type of anes­thesia used may impact the success outcomes for mechanical thrombectomy. General anesthesia (GA) may improve procedural safety preventing body movement as well as protecting the air­way, while conscious sedation (CS) allows for neurologic moni­toring with hemodynamic stability and a quicker puncture time [80]. Due to the lack of a consensus in the present literature, a preference for which type of anesthesia to use is undetermined.
Initial retrospective studies often based their anesthesia choice on patient characteristics and the comfort level of the administra­tor. A retrospective study featuring 1174 patients from 2009 to 2013 concluded that GA was inferior to CS; however, there was limited data on the important factors such as blood pressure and the NIHSS.Furthermore, their outcomes studied were only mor­tality and length of stay [80]. Conversely, another retrospective database study of 2512 patients concluded the opposite: that CS was superior to GA for stroke interventions [81].
220
O. Doron et al.
Intra-arterial Neuroprotection, Middle Vessel Occlusion, andAI-Powered Tools inAIS: New Frontiers
A deeper understanding of the use of EVT for AIS treatment pres­ents an opportunity to address multiple prevention and treatment aspects, attributable to the various technological innovations com­bined with extensive data on patients and interventions, and unprecedented computing processing. In this chapter, we focus specically on potential innovative directions in endovascular invasive therapies which could drive future AIS treatment.
Stroke Secondary toDistal Medium-Vessel Occlusion
Distal medium-vessel occlusion (DMVO) recanalization pres­ents further challenges to vessel recanalization, despite signi­cantly improved LVO recanalization rates. Around 35–40% of AIS cases occur due to LVO, while 25–40% are caused by medium-vessel occlusions (MeVOs). Characterized by distal occlusion location and less ischemia, MeVO strokes have better outcomes when compared with LVO strokes, but cohort studies indicate that the outcomes are frequently poor, despite best med­ical management [82].
The exact denition of a medium-sized vessel also requires consensus, as vessel size and anatomy may be subjected to interobserver variability. MeVO was dened as an occlusion of the M2/M3 middle cerebral artery/A2/A3 anterior cerebral artery and P2/P3 posterior cerebral artery segments in a study with pooled data from two multicenter prospective cohorts. In this study, only 50.0% of patients with DMVO achieved an excellent outcome (mRS score, 0–1) at 90 days, and 67.4% achieved an independent outcome (mRS score, 0–2). Moreover, the authors found that intravenous alteplase was signicantly associated with lower mRS scores in mRS shift analysis, but no signicant asso­ciation with excellent outcome (mRS score, 0–1) was noted.
ab
10 Endovascular Management and Treatment of Acute Ischemic…
221
Moreover, even in the alteplase group, early recanalization was achieved in <50% of study cohort, suggesting insufcient efcacy of intravenous alteplase as a stand-alone treatment for DMVO strokes [83].
Data from a preliminary meta-analysis of 12 nonrandomized studies indicated that EVT for patients with occlusions of M2 seg­ment of middle cerebral artery that can be safely accessed is asso­ciated with high recanalization rates and good clinical outcomes [84].
Until recently, endovascular treatment of DMVO was consid­ered to have a high risk-benet ratio with less severe clinical de­cits and increased risk of iatrogenic complications. Additionally, the isolated nature of decits associated with these and other MeVOs (A2/A3/M3/P2/P3) such as abulia, quadrantanopia, apha­sia, and ataxia makes NIHSS-based and protocolized patient selection challenging (Fig. 10.4).
Determining the infarct core and penumbra accurately in MeVO stroke may be challenging or not possible at all, as recent literature suggests that we presently lack the ability to precisely delineate infarct “core” with the commonly used imaging modali-
Fig. 10.4 Patient who presented with a distal right middle cerebral artery occlusion. (a) Initial injection of the right internal carotid artery, parenchymal phase, demonstrates an occlusion of a distal right middle cerebral artery branch (M3/4) (yellow arrow) resulting in an area of lack of parenchymal blood ow (blue arrow). (b) Patient underwent aspiration thrombectomy resulting in recanalization of the occluded branch